Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-10-13
- Last Posted Date
- 2015-01-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT01219933
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01215123
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2015-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT01214733
A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2010-10-05
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 607
- Registration Number
- NCT01214720
An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease on Dialysis (HORTENSIA)
Completed
- Conditions
- Anemia
- First Posted Date
- 2010-10-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 419
- Registration Number
- NCT01213485
Study of ANA773 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) to Assess Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)
Phase 1
Completed
- Conditions
- HCV Infection
- Interventions
- Drug: ANA773Drug: Placebo
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 75
- Registration Number
- NCT01211626
- Locations
- 🇳🇱
Erasmus MC (EMC), Rotterdam, Netherlands
🇳🇱Academisch Medisch Centrum (AMC), Amsterdam, Netherlands
🇳🇱PRA Clinical Research Unit, Groningen, Netherlands
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs
Phase 3
Terminated
- Conditions
- Spondylitis, Ankylosing
- Interventions
- Drug: PlaceboBiological: tocilizumab
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 306
- Registration Number
- NCT01209702
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 113
- Registration Number
- NCT01209689
A Single Ascending And Multiple Ascending Dose Study of RO5271983 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: Placebo - MADDrug: RO5271983 - SADDrug: Placebo - SADDrug: RO5271983 - MAD
- First Posted Date
- 2010-09-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 82
- Registration Number
- NCT01209221
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
Phase 2
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 74
- Registration Number
- NCT01204697
© Copyright 2025. All Rights Reserved by MedPath